Lilly reports first-quarter 2025 financial results and highlights pipeline momentum
Revenue in Q1 2025 increased 45% to $12.73 billion driven by volume growth from Mounjaro and Zepbound.Pipeline progress included positive Phase 3 trial results for orforglipron (small molecule oral GLP-1